Marker Therapeutics
MRKR
45 hedge funds and large institutions have $7.56M invested in Marker Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 5 closing their positions.
3% more capital invested
Capital invested by funds: $7.36M → $7.56M (+$204K)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.22% less ownership
Funds ownership: 2.66% → 2.45% (-0.22%)
6% less funds holding
Funds holding: 48 → 45 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
+$55.1K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$34.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15.8K |
| 4 |
NRS
Neville Rodie & Shaw
New York
|
+$11K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$358K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$199K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$48K |
| 4 |
Two Sigma Investments
New York
|
-$44.5K |
| 5 |
Renaissance Technologies
New York
|
-$42.7K |
MRKR Hedge Fund Activity: Q3 2022 in Review
45 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2022, worth a combined $7.56M — up 2.8% from $7.36M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MRKR and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Matrix Asset Advisors, adding an estimated $55.1K. The largest seller was Long Focus Capital Management, cutting an estimated $358K.
- 45 institutional investors held Marker Therapeutics (MRKR) as of Q3 2022, down from 48 in Q2 2022.
- Funds reported $7.56M of Marker Therapeutics stock for Q3 2022, up 2.8% quarter-over-quarter.
- 2 funds opened new Marker Therapeutics positions in Q3 2022 and 5 closed out, a net change of -3 holders.
- The largest Marker Therapeutics buyer in Q3 2022 was Matrix Asset Advisors, an estimated $55.1K added.
- The largest Marker Therapeutics seller in Q3 2022 was Long Focus Capital Management, an estimated $358K sold.
Based on aggregated 13F filings for Q3 2022.